Arcturus Therapeutics Holdings Inc. (ARCT) Posts Interim OTCD Phase 2 Data; Unveils LUNAR 2.0
Arcturus reported interim Phase 2 data for ARCT-810 in OTC deficiency and introduced LUNAR 2.0, which showed up to ~40-fold potency gains in NHPs. It plans to integrate ARCT-2601 into the ongoing Phase 2 near year-end, and agreed to acquire myNEO, expected to close in October.Material DetailsContex…